MoonLake Immunotherapeutics
MLTX
$55.65
$0.811.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.13% | 62.00% | 33.04% | 36.81% | 54.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.50% | 139.58% | 229.90% | 232.23% | 131.90% |
| Operating Income | -98.50% | -139.58% | -229.90% | -232.23% | -131.90% |
| Income Before Tax | -126.73% | -190.59% | -491.02% | -210.79% | -99.95% |
| Income Tax Expenses | 20.25% | 118.57% | -7.22% | 218.69% | 682.18% |
| Earnings from Continuing Operations | -126.39% | -190.23% | -488.23% | -210.81% | -100.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 68.90% | 103.64% | 75.71% | -66.99% | -77.78% |
| Net Income | -127.55% | -192.14% | -513.20% | -275.45% | -139.34% |
| EBIT | -98.50% | -139.58% | -229.90% | -232.23% | -131.90% |
| EBITDA | -98.29% | -141.67% | -229.14% | -232.06% | -129.36% |
| EPS Basic | -126.06% | -189.37% | -482.68% | -219.53% | -66.45% |
| Normalized Basic EPS | -127.16% | -190.96% | -501.35% | -266.95% | -88.79% |
| EPS Diluted | -126.06% | -189.37% | -482.68% | -219.53% | -66.45% |
| Normalized Diluted EPS | -127.16% | -190.96% | -501.35% | -266.95% | -88.79% |
| Average Basic Shares Outstanding | 0.65% | 0.95% | 5.27% | 17.53% | 43.82% |
| Average Diluted Shares Outstanding | 0.65% | 0.95% | 5.27% | 17.53% | 43.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |